Immuneering reported updated Phase 2a data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer—well above historical benchmarks cited by the company. Progression‑free survival and interim safety also compared favorably to external chemotherapy data. The company emphasized that PFS separation bolsters the OS signal and plans a pivotal randomized trial enrolling ~510 patients with overall survival as the primary endpoint, expected to start around mid‑2026. Management said expanded cohort data from 50 patients due in 1H 2026 will further inform trial design. Investors reacted with volatile trading after the update; Immuneering framed the readout as a catalyst to move into a registrational program if larger confirmatory data hold.